扰乱CARMA3信号与三类逆转Sorafenib阻力在肝细胞癌
Wan-Yu Wang1, Tung-Wei Hsu1,2, Yen-Hao Su1,3,4,5,6,7
1Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.
International journal of medical sciences
|November 10, 2025
概括
特里普托利德通过向CARMA3.3,克服了肝癌的耐药性. 这通过促进细胞死亡途径和反应性氧物种积累来提高化疗的有效性.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 癌症药物耐药性机制 癌症药物耐药性机制
- 分子瘤学分子瘤学
背景情况:
- 肝细胞癌 (HCC) 是一种普遍存在的肝癌,治疗选择有限.
- 索拉费尼布是先进的HCC的第一线疗法,提供了最小的生存益处,并且经常导致药物耐药性.
- 了解HCC耐药性的分子基础对于开发有效疗法至关重要.
研究的目的:
- 研究CARMA3 (CARD10) 在HCC化学抵抗中的作用.
- 探索三托利德作为HCC中的化学敏感剂的潜力.
- 阐明托利德克服药物耐药性的分子机制.
主要方法:
- 研究了CARMA3表达及其在HCC化学抵抗中的作用.
- 评估了ptolide 对 HCC 细胞对化疗敏感性的影响.
- 分析了triptolide对CARMA3表达,活性氧物种 (ROS) 水平和铁亡的影响.
主要成果:
- 发现CARMA3有助于肝细胞癌的化学抵抗.
- 特里普托利德在HCC模型中表现出增强化学敏感性的能力.
- 三类药物治疗导致CARMA3表达减少和ROS积累增加,使细胞对铁灭症敏感.
结论:
- 在HCC中,CARMA3在调解化学抵抗方面发挥着重要作用.
- 特里普托利德通过降低CARMA3的调节和诱导ROS积累,起到化学敏感剂的作用.
- 向CARMA3和调节ROS/铁亡是一种新的治疗策略,可以克服HCC的耐药性.
更多相关视频
07:20A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery
Published on: February 28, 2020
10.4K
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.0K
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
